Cazitel Plus XL Tablets For Dogs
Cazitel Plus XL Tablets For Dogs
Authorised
- Praziquantel
- Febantel
- Pyrantel embonate
Product identification
Medicine name:
Cazitel Plus XL Tablets For Dogs
Active substance:
- Praziquantel
- Febantel
- Pyrantel embonate
Target species:
-
Dog
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Praziquantel175.00/milligram(s)1.00Tablet
-
Febantel525.00/milligram(s)1.00Tablet
-
Pyrantel embonate504.00/milligram(s)1.00Tablet
Pharmaceutical form:
-
Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QP52AA51
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription except for some pack sizes
Authorisation status:
-
Valid
Authorised in:
-
Sweden
Package description:
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
- Available only in Swedish
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Chanelle Pharmaceuticals Manufacturing Limited
Marketing authorisation date:
Manufacturing sites for batch release:
- Chanelle Pharmaceuticals Manufacturing Limited
Responsible authority:
- Swedish Medical Products Agency
Authorisation number:
- 47791
Date of authorisation status change:
Reference member state:
-
Ireland
Procedure number:
- IE/V/0243/002
Concerned member states:
-
Austria
-
Belgium
-
Bulgaria
-
Cyprus
-
Czechia
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Italy
-
Latvia
-
Lithuania
-
Luxembourg
-
Netherlands
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
English (PDF)
Download Published on: 1/03/2026
Swedish (PDF)
Published on: 18/07/2025
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.
Swedish (PDF)
Published on: 18/07/2025
Labelling
This document does not exist in this language (English). You can find it
in another language below.
Swedish (PDF)
Published on: 20/06/2023
Updated on: 26/06/2023
Combined File of all Documents
English (PDF)
Download Published on: 1/03/2026